Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis
Ayalew Tefferi, Animesh Pardanani, Naseema Gangat
Haematologica (2023) Vol. 108, Iss. 11, pp. 2919-2932
Open Access | Times Cited: 36

Showing 26-50 of 36 citing articles:

JAK2 inhibitor treatment of anemia in myelofibrosis
Ayalew Tefferi, Alessandro M. Vannucchi
American Journal of Hematology (2023) Vol. 98, Iss. 7, pp. 995-997
Closed Access | Times Cited: 2
Jaktinib and momelotinib for the treatment of myelofibrosis—Birds of a feather?
Ayalew Tefferi
American Journal of Hematology (2023) Vol. 98, Iss. 10, pp. 1517-1519
Closed Access | Times Cited: 2
Targeting anemia in myeloid neoplasms
Naseema Gangat, Ayalew Tefferi
American Journal of Hematology (2024) Vol. 99, Iss. 9, pp. 1663-1666
Closed Access
Synaptotagmin 13 Could Drive the Progression of Esophageal Squamous Cell Carcinoma Through Upregulating ACRV1
Longlong Shao, Bin Li
DNA and Cell Biology (2024)
Closed Access
Comprehensive analysis of a necroptosis-associated diagnostic signature for myelodysplastic syndromes based on single-cell RNA-seq and bulk RNA-seq
Huimin Zhang, Li Zhang, Xiaoning Liang, et al.
Hereditas (2024) Vol. 161, Iss. 1
Open Access
FDA greenlights momelotinib (Ojjaara) as the exclusive treatment for myelofibrosis patients battling anemia
Memuna Jehanzeb, Urooj Iqbal, Nesrine Farhat, et al.
Annals of Medicine and Surgery (2024) Vol. 86, Iss. 12, pp. 6916-6917
Open Access
When and how to transplant in myelofibrosis – recent trends
Naman Sharma, Giuseppe Gaetano Loscocco, Naseema Gangat, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2024), pp. 1-19
Closed Access
TO MARKET, TO MARKET—2023: SMALL MOLECULES
Erika Araujo, Björn Bartels, Ian M. Bell, et al.
Medicinal chemistry reviews (2024), pp. 417-551
Closed Access
Momelotinib – a promising advancement in the management of myelofibrosis in adults with anemia
Muhammad Furqan, Malik Olatunde Oduoye
Frontiers in Oncology (2024) Vol. 14
Open Access
Treatment of primary myelofibrosis: Where we stand today?
Andrija Bogdanović, Danijela Leković
Srpski medicinski casopis Lekarske komore (2024) Vol. 5, Iss. 3, pp. 404-418
Open Access
CALR mutations possess unique prognostic relevance in myelofibrosis—before and after transplant
Ayalew Tefferi, Alessandro M. Vannucchi
Bone Marrow Transplantation (2023) Vol. 59, Iss. 1, pp. 1-3
Open Access | Times Cited: 1
Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group
Harinder Gill, Garret M. K. Leung, Melissa Ooi, et al.
Clinical and Experimental Medicine (2023) Vol. 23, Iss. 8, pp. 4199-4217
Closed Access
Previous Page - Page 2

Scroll to top